Showing results (1-10 of 380) with videos related to
Sort By:
Pageof 38
Expert Opinion on Drug Safety|November 6, 2008
Olanzapine: review of safety 2008Joshua T Kantrowitz, Leslie CitromeCNS Drugs|February 3, 2011
Schizoaffective disorder: a review of current research themes and pharmacological managementJoshua T Kantrowitz, Leslie CitromeExpert Review of Neurotherapeutics|February 28, 2012
Lurasidone for schizophrenia: what's different?Joshua T Kantrowitz, Leslie CitromeExpert Review of Neurotherapeutics|July 11, 2009
Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?Leslie Citrome, Joshua T KantrowitzClinical Therapeutics|August 25, 2009
A review of tolerability and abuse liability of gamma-hydroxybutyric acid for insomnia in patients with schizophreniaJoshua T Kantrowitz, Leslie Citrome, Daniel C JavittPostgraduate Medicine|December 10, 2019
New discoveries for an old drug: a review of recent olanzapine researchAmir M Meftah, Elizabeth Deckler, Leslie Citrome, et al.CNS Drugs|August 13, 2020
Targeting Serotonin 5-HT2A Receptors to Better Treat Schizophrenia: Rationale and Current ApproachesJoshua T KantrowitzCNS Drugs|April 12, 2017
Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Joshua T KantrowitzSchizophrenia Research|February 21, 2018
N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophreniaJoshua T KantrowitzCNS Drugs|October 16, 2021
Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future DirectionsJoshua T KantrowitzPageof 38